Registry study of genetic changes in melanoma patients in Taiwan
Studies genetic changes in people with melanoma of the extremities.
Plain-language title generated from the registry record
Registry title: The Registry Study of Genetic Alterations of Melanoma in Taiwan
Key facts
- Where
- Chiayi City, Kaohsiung City, Sindian City, Taichung, Tainan, Taipei, and Taoyuan, TaiwanSee the 16 sites
Where in Taiwan
- Chang-Gung Memorial Hospital - ChiayiChiayi City, TaiwanTaking people
- Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanTaking people
- Kaohsiung Medical UniversityKaohsiung City, TaiwanTaking people
- National Taiwan University Hospital ,NTUH Hsin-Chu BranchSindian City, TaiwanTaking people
- China Medical University HospitalTaichung, TaiwanTaking people
- Chung Shan Medical University HospitalTaichung, TaiwanTaking people
- Taichung Veterans General HospitalTaichung, TaiwanTaking people
- National Cheng Kung University HospitalTainan, TaiwanTaking people
- Koo Foundation Sun Yat-Sen Cancer CenterTaipei, TaiwanTaking people
- MacKay Memorial HospitalTaipei, TaiwanTaking people
- National Taiwan University HospitalTaipei, TaiwanTaking people
- Taipei Medical University -Ministry of Health and Welfare Shuang-Ho HospitalTaipei, TaiwanTaking people
- Taipei Veterans General HospitalTaipei, TaiwanTaking people
- Wan Fang Hospital, Taipei Medical UniversityTaipei, TaiwanTaking people
- Chang Gung Memorial Hospital, LinkouTaoyuan, TaiwanTaking people
- Taoyuan General Hospital, Ministry of Health and WelfareTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Health Research Institutes, Taiwan
- Trial code
- NCT06952400
- Record updated
- 6 May 2025
- Original description
Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.Read full original descriptionShow less
T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan
Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.
Inclusion: Age > 18 years old; Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded); ECOG performance status < 3; Cohort 1(early acral melanoma): melanoma, stage I/II; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable / metastatic melanoma, stage III/IV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4; Willingness to provide archival or newly obtained tumor tissues for this study proposal; Life expectancy more than 3 months -; Patients fully understand the protocol with the willingness to have regular follow-up.
Exclusion: Inability to cooperate by providing a complete medical history; No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date); Undesirable compliance (Mental status is not fit for further treatment or data collection.).